This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
This money was used for improvements and security enhancements at research and storage facilities. Safety of nuclear facilities in Russia has been significantly improved since the stabilization of political and economical turmoil of the early 1990s. For example, in 1993 there were 29 incidents ranking above level 1 on the International Nuclear Event Scale, and this number dropped under four per year in 1995–2003. The number of employees receiving annual radiation doses above 20 mSv, which is equivalent to a single full-body CT scan, saw a strong decline around 2000. In November 2015, the Russian government approved a federal program for nuclear and radiation safety for 2016 to 2030 with a budget of 562 billion rubles (ca. 8 billion USD). Its key issue is "the deferred liabilities accumulated during the 70 years of the nuclear industry, particularly during the time of the Soviet Union". About 73% of the budget will be spent on decommissioning aged and obsolete nuclear reactors and nuclear facilities, especially those involved in state defense programs; 20% will go in processing and disposal of nuclear fuel and radioactive waste, and 5% into monitoring and ensuring of nuclear and radiation safety.
From 1933 onwards, poet Victor Neuburg edited a section called "The Poet's Corner" in a British newspaper, the Sunday Referee. Here he encouraged new talent by awarding weekly prizes. One prize went to the then-unknown Thomas, and the publisher of the Sunday Referee sponsored and Neuburg arranged for the publication of Thomas's first book, 18 Poems, in December 1934. The anthology was published by Fortune Press, in part a vanity publisher that did not pay its writers and expected them to buy a certain number of copies themselves. 18 Poems was noted for its visionary qualities which led to critic Desmond Hawkins writing that the work was "the sort of bomb that bursts no more than once in three years". The volume was critically acclaimed, netting him new admirers from the London poetry world, including Edith Sitwell and Edwin Muir. When "Light breaks where no sun shines" appeared in The Listener in 1934, it caught the attention of three senior figures in literary London, T. S. Eliot, Geoffrey Grigson and Stephen Spender. In December 1935, Thomas contributed the poem "The Hand That Signed the Paper" to Issue 18 of the bi-monthly New Verse. In 1936, his next collection Twenty-five Poems, published by J. M. Dent, also received much critical praise. Two years later, in 1938, Thomas won the Oscar Blumenthal Prize for Poetry; it was also the year in which New Directions offered to be his publisher in the United States. In all, he wrote half his poems while living at Cwmdonkin Drive before moving to London. During this time Thomas's reputation for heavy drinking developed.
Rodríguez-Franco et al. (2026) report evidence of dental anomalies in Columbian mammoth specimens from 15 localities in the Basin of Mexico. Evidence from the study of carbon, oxygen and strontium isotope composition of Columbian mammoth remains from the Colby Site (Wyoming, United States), indicative of the studied mammoths feeding mainly on C3 plants and having a range of less than 250 km, is presented by Doering, Mackie & Herron (2026), who interpret the assemblage of mammoth remains from the studied site as more likely resulting from multiple hunting episoded than from a single massive one. Evidence indicating that morphology of the astragalus of Quaternary elephantids was influenced by their body size to a greater degree than by their phylogenetic affinities is presented by Fidalgo et al. (2026).
In the 19th and early 20th century, modernist art, politics, science, and culture have come to dominate not only Western Europe and North America, but almost every area on the globe, including movements thought of as opposed to the western world and globalization. The modern era is closely associated with the development of individualism, capitalism, socialism, urbanization and a belief in the positive possibilities of technological and political progress. The brutal wars and other conflicts of this era, many of which come from the effects of rapid change, and the connected loss of strength of traditional religious and ethical norms, have led to many reactions against modern development. Optimism and the belief in constant progress have been most recently criticized by postmodernism, while the dominance of Western Europe and North America over the rest of the world has been criticized by postcolonial theory.
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine. Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects, and was thought to have more local anesthetic effect than morphine, though with a somewhat greater tendency to cause reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered. Consequently, it was thought to be useful in treating pain in addicts who were being detoxified from other opioid drugs. It is a Schedule I drug in the US, considered to have high potential for abuse and no medical applications, and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308. Myrophine is a Class A controlled substance in the UK, and is on the UN's Yellow list.
Sources: en.wikipedia.org
Amanda Grace Paulovich is an oncologist, and a pioneer in proteomics using multiple reaction monitoring mass spectrometry to study tailored cancer treatment. Paulovich received a BS in Biological Sciences from Carnegie Mellon University in 1988, a PhD in Genetics from University of Washington in 1996, under the direction of Leland Hartwell. She also received a MD from University of Washington in 1998. Follow her residency in Internal Medicine at Massachusetts General Hospital, she also completed a Postdoctoral Fellowship in Computational Biology at the Massachusetts Institute of Technology Whitehead Center for Genomic Research in 2003, and a Fellowship in Medical Oncology at the Dana Farber Cancer Institute in 2004.
In molecular biology, Enhancer of rudimentary homolog is a protein that in humans is encoded by the ERH gene. The Drosophila protein enhancer of rudimentary protein is a small protein of 104 amino acids. It has been found to be an enhancer of the rudimentary gene, involved in pyrimidine biosynthesis. From an evolutionary point of view, enhancer of rudimentary is highly conserved and has been found to exist in probably all multicellular eukaryotic organisms. It has been proposed that this protein plays a role in the cell cycle. PDBe-KB provides an overview of all the structure information available in the PDB for Human Enhancer of rudimentary homolog (ERH) PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Enhancer of rudimentary homolog (ERH)
Motilin has 22 amino acids and molecular weight of 2698 daltons. In extract from human gut and plasma, there are two basic forms of motilin. The first molecular form is the polypeptide of 22 amino acids. The second form, on the other hand, is larger and contains the same 22 amino acids as the first form but includes an additional carboxyl-terminus end. The sequences of amino acids of motilin is: Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln. The structure and dynamics of the gastrointestinal peptide hormone motilin have been studied in the presence of isotropic q = 0.5 phospholipid bicelles. The NMR solution structure of the peptide in acidic bicelle solution was determined from 203 NOE-derived distance constraints and six backbone torsion angle constraints. Dynamic properties for the 13Cα→1H vector in Leu-10 were determined for motilin specifically labeled with 13C at this position by analysis of multiple-field relaxation data. The structure reveals an ordered alpha-helical conformation between Glu-9 and Lys-20. The N-terminus is also well structured with a turn resembling that of a classical beta-turn. The 13C dynamics clearly show that motilin tumbles slowly in solution, with a correlation time characteristic of a large object.
A crowbar is a lever consisting of a metal bar with a single curved end and flattened points, used to force two objects apart or gain mechanical advantage in lifting; often the curved end has a notch for removing nails. Crowbars have a variety of uses, with specific types of crowbar being more suited to certain tasks. The design can be used as any of the three lever classes. The curved end is usually used as a first-class lever, and the flat end as a second-class lever. Designs made from thick flat steel bar are often referred to as utility bars. Crowbars are occasionally used by criminals as a tool for forcible entry or as an offensive weapon. The use of a crowbar as a weapon is also common in fictional media, and it is considered an iconic part of the Half-Life franchise.
After escaping in the present, he seeks out his ex-girlfriend Myra and pilots a ninja-themed Kaijuki called Shinobi Shadow (シノビシャドー, Shinobi Shadō) to stop the Dekarangers, who destroy the Kaijuki with Dekaranger Robo before deleting Sheik with the D-Bazooka. Sheik is voiced by Hideaki Kusaka (日下 秀昭, Kusaka Hideaki). Bileezian Vino (ビリーザ星人ヴィーノ, Birīza Seijin Vīno): An old academy friend of Hoji's from Planet Bileez who retired from S.P.D. out of disenchantment, was lured into a criminal lifestyle by the money he earned from his skills, became a mercenary, reconfigured his body into a monstrous form, and assumed the identity of Gigandes (ギガンテス, Gigantesu) to commit indiscriminate mass murder. In the present, he is hired by Ben G and Agent Abrella to assassinate Kruger and retrieve information on the Deka Base, respectively. Vino succeeds in the latter task before he enlarges himself and is deleted by Dekaranger Robo. Vino is voiced by Naoya Gomoto (郷本 直也, Gōmoto Naoya), who also portrays his original form. Kajimerian Ben G (カジメリ星人ベン・G, Kajimeri Seijin Ben G): A criminal from Planet Kajimeri who was charged with mass-murder and swore revenge on Kruger, following a near-death experience amidst a chase between them that turned the former into a cyborg. As part of his revenge, Ben G tasks a Batsuroid with piloting a drill-themed Kaijuki called Terrible Terror (テリブルテーラー, Teriburu Tērā) to distract the Dekarangers while he infiltrates the Deka Base and kidnaps Swan Shiratori. Terrible Terror is destroyed by Dekaranger Robo, while Ben G is deleted by Deka Master.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.